Scott Carver
Family Medicine · Satsuma, ALNPI 1023112257
Payments from drug & device makers
Across 349 payments — averaging $12.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$980
- Galt Pharmaceuticals, LLC$901
- Novartis$558
- AbbVie$423
- Pfizer$328
- Johnson & Johnson$168
- plus $896 from 24 others
What the payments were for
- Food & beverage$4,255100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 147 | $980 |
| Galt Pharmaceuticals, LLC | 1 | $901 |
| Novartis | 54 | $558 |
| AbbVie(2 entities) | 43 | $423 |
| Pfizer | 44 | $328 |
| Johnson & Johnson | 12 | $168 |
| Atland Pharmaceuticals, LLC | 1 | $164 |
| Abbott | 3 | $69 |
| Lilly USA, LLC | 5 | $68 |
| Daiichi Sankyo Inc. | 3 | $59 |
| Teva Pharmaceuticals USA, Inc. | 4 | $58 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $53 |
| Sunovion Pharmaceuticals Inc. | 3 | $36 |
| Boehringer Ingelheim | 2 | $36 |
| Otsuka America Pharmaceutical, Inc. | 2 | $34 |
| AstraZeneca | 2 | $33 |
| Nabriva Therapeutics, PLC | 2 | $31 |
| Arbor Pharmaceuticals, Inc. | 2 | $29 |
| GSK | 2 | $28 |
| Merck | 2 | $27 |
| Bayer | 2 | $27 |
| Amgen | 2 | $25 |
| Mylan Specialty L.p. | 1 | $19 |
| Seqirus USA Inc | 1 | $17 |
| Viatris Specialty LLC | 1 | $15 |
| UCB, Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $13 |
| Phathom Pharmaceuticals, Inc. | 1 | $12 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,255 in reported general payments places this provider in the 80th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 161 | $219,347 |
| JardianceEmpagliflozin | 167 | $187,398 |
| OzempicSemaglutide | 132 | $179,680 |
| AustedoDeutetrabenazine | 58 | $173,191 |
| EliquisApixaban | 350 | $146,663 |
| TrulicityDulaglutide | 45 | $59,657 |
| JanuviaSitagliptin Phosphate | 36 | $54,473 |
| TivicayDolutegravir Sodium | 15 | $47,600 |
| XareltoRivaroxaban | 35 | $37,829 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 47 | $37,640 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 73 | $37,557 |
| LinzessLinaclotide | 38 | $32,622 |
| NuplazidPimavanserin Tartrate | 22 | $27,157 |
| TradjentaLinagliptin | 36 | $25,189 |
| FarxigaDapagliflozin Propanediol | 36 | $24,618 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $68 | $279,004206 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Tradjenta | $36 | $250,144276 claims |
| Novo NordiskOzempic, Levemir | $980 | $184,278166 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $58 | $173,19158 claims |
| PfizerEliquis, Abrysvo | $328 | $153,269371 claims |
| MerckJanuvia, Janumet Xr, Belsomra | $27 | $75,43464 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $28 | $55,34786 claims |
| Johnson & JohnsonXarelto, Procrit | $168 | $50,14949 claims |
| AbbVieLinzess | $423 | $32,62238 claims |
| AstraZenecaFarxiga, Symbicort | $33 | $29,41548 claims |
| NovartisEntresto | $558 | $23,49934 claims |
| Astellas Pharma US IncMyrbetriq | $13 | $12,42022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Satsuma
- Michael VaughnBirmingham$9.9M
- William NixonGuntersville$7.1M
- Randall QuinnCullman$5.4M
- Matthew CaldwellAthens$4.1M
- Michael CarterHuntsville$3.4M
- Howard RubensteinSaraland$3.3M
- Randle MiddletonHuntsville$3.3M
- Aaron KarrSheffield$3.1M
- Nidal MorrarFoley$3M
- Timothy HowardHuntsville$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.